Akari Therapeutics Plc - ADR
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Akari Therapeutics Plc - ADR
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
/ 
Frequently asked questions
To buy Akari Therapeutics Plc - ADR stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Akari Therapeutics Plc - ADR by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Akari Therapeutics Plc - ADR is AKTX:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Akari Therapeutics Plc - ADR has its primary listing on NASDAQ (Small cap). You can trade Akari Therapeutics Plc - ADR with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Akari Therapeutics Plc - ADR is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Akari Therapeutics Plc - ADR as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Akari Therapeutics Plc - ADR.